MedTrace Logo

ET-01 in Subjects With Lateral Canthal Lines

NCT03326856 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2022-04-21

Study results available
· View outcomes & findings →

Summary

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

Conditions

  • Lateral Canthal Lines
  • Crow's Feet

Interventions

BIOLOGICAL

botulinum toxin, Type A

topical liniment

BIOLOGICAL

Vehicle

Vehicle Formulation

Sponsors & Collaborators

  • Eirion Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Klaus Theobald, MD, PhD · Eirion Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-25
Primary Completion
2018-06-11
Completion
2018-11-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03326856 on ClinicalTrials.gov